newsfilter
← Latest News
Business Wire·

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Obtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in